Review

Maturation of Stem Cell-Derived Beta-cells Guided by the Expression of Urocortin 3

Talitha van der Meulen, Mark O. Huising

Manuscript submitted March 28, 2013; accepted June 26, 2013.

Keywords: type 1 diabetes, insulin, stem cell, pancreatic beta-cell, pancreas development, transplantation, urocortin 3, UCN3, CRF receptor, CRH receptor

Abstract

Type 1 diabetes (T1D) is a devastating disease precipitated by an autoimmune response directed at the insulin-producing beta-cells of the pancreas for which no cure exists. Stem cell-derived beta-cells show great promise for a cure as they have the potential to supply unlimited numbers of cells that could be derived from a patient's own cells, thus eliminating the need for immunosuppression. Current in vitro protocols for the differentiation of stem cell-derived beta-cells can successfully generate pancreatic endoderm cells. In diabetic rodents, such cells can differentiate further along the beta-cell lineage until they are eventually capable of restoring normoglycemia. While these observations demonstrate that stem cell-derived pancreatic endoderm has the potential to differentiate into mature, glucose-responsive beta-cells, the signals that direct differentiation and maturation from pancreatic endoderm onwards remain poorly understood. In this review, we analyze the sequence of events that culminates in the formation of beta-cells during embryonic development. and summarize how current protocols to generate beta-cells have sought to capitalize on this ontogenic template. We place particular emphasis on the current challenges and opportunities which occur in the later stages of beta-cell differentiation and maturation of transplantable stem cell-derived beta-cells. Another focus is on the question how the use of recently identified maturation markers such as urocortin 3 can be instrumental in guiding these efforts.

Fulltext: HTML , PDF (601KB)

This article has been cited by other articles:

	Virgin Beta Cells Persist throughout Life at a Neogenic Niche within Pancreatic Islets van der Meulen T, Mawla AM, DiGruccio MR, Adams MW, Nies V, Dolleman S, Liu S, Ackermann AM, Caceres E, Hunter AE, Kaestner KH, Donaldson CJ, Huising MO Cell Metab 2017. 25(4):911-926
	All mixed up: defining roles for beta-cell subtypes in mature islets Liu JS, Hebrok M Genes Dev 2017. 31(3):228-240
	Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas Buishand FO, Arkesteijn GJ, Feenstra LR, Oorsprong CW, Mestemaker M, Starke A, Speel EJ, Kirpensteijn J, Mol JA Stem Cells Dev 2016. 25(11):826-835
	Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome Temur M, Yilmaz Ö, Aksun S, Özün Özbay P, Calan M, Küme T, Karakulak M, Korkmaz HA Gynecol Endocrinol 2016. 32(3):218-222
	Recent advance in diabetes therapy: pancreatic beta cell regeneration approaches Chala TS, Ali GY Diabetes Manag (Lond) 2016. 6(6):108-118
	Human Embryonic Stem Cells and Induced Pluripotent Stem Cells: The Promising Tools for Insulin-Producing Cell Generation Leeanansaksiri W, Rattananinsruang P, Dechsukhum C Stem Cell Res 2016. In press
	Ethical issues in biomedical use of human embryonic stem cells (hESCs) Ghosh D, Mehta N, Patil A, Sengupta J J Reprod Health Med 2016. 2(2):S37-S47
	Designing a VAR2CSA-based vaccine to prevent placental malaria Fried M, Duffy PE Vaccine 2015. 33(52):7483-7488
	Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion van der Meulen T, Donaldson CJ, Caceres E, Hunter AE, Cowing-Zitron C, Pound LD, Adams MW, Zembrzycki A, Grove KL, Huising MO Nat Med 2015. 21(7):769-776
	Reversal of beta cell de-differentiation by a small molecule inhibitor of the TGFbeta pathway Blum B, Roose AN, Barrandon O, Maehr R, Arvanites AC, Davidow LS, Davis JC, Peterson QP, Rubin LL, Melton DA Elife 2014. 3:e02809